S&P 500   4,299.70 (+0.59%)
DOW   33,666.34 (+0.35%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
S&P 500   4,299.70 (+0.59%)
DOW   33,666.34 (+0.35%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
S&P 500   4,299.70 (+0.59%)
DOW   33,666.34 (+0.35%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
S&P 500   4,299.70 (+0.59%)
DOW   33,666.34 (+0.35%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
NASDAQ:ANGO

AngioDynamics (ANGO) Stock Forecast, Price & News

$7.32
+0.08 (+1.10%)
(As of 09/28/2023 ET)
Compare
Today's Range
$7.16
$7.45
50-Day Range
$7.02
$9.00
52-Week Range
$6.72
$21.88
Volume
408,773 shs
Average Volume
454,776 shs
Market Capitalization
$290.38 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.33

AngioDynamics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
136.8% Upside
$17.33 Price Target
Short Interest
Healthy
4.86% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.99
Upright™ Environmental Score
News Sentiment
0.50mentions of AngioDynamics in the last 14 days
Based on 12 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.33) to ($0.16) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.43 out of 5 stars

Medical Sector

217th out of 969 stocks

Surgical & Medical Instruments Industry

29th out of 100 stocks


ANGO stock logo

About AngioDynamics (NASDAQ:ANGO) Stock

AngioDynamics, Inc. provides invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology in the United States and internationally. It offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium for treatment of peripheral arterial disease. The company's thrombus management portfolio includes AlphaVac system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac circuit is indicated for extracorporeal circulatory support for periods of up to six hours including off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. In addition, it offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters and diagnostic and interventional guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits used during peripheral diagnostic and interventional procedures. The company also provides drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro Access kits provides interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero MTA System includes solero microwave generator and the specially designed solero MW applicators. AngioDynamics, Inc. was founded in 1988 and is headquartered in Latham, New York.

ANGO Price History

ANGO Stock News Headlines

AngioDynamics (ANGO) Scheduled to Post Earnings on Wednesday
Unlock the treasure on Mount Olympus with this little-known mining stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
Why AngioDynamics Stock Popped on Monday
U.S. drive to onshore battery supply chains could create big winners in lithium
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
See More Headlines
Receive ANGO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AngioDynamics and its competitors with MarketBeat's FREE daily newsletter.

ANGO Company Calendar

Last Earnings
7/12/2023
Today
9/28/2023
Next Earnings (Confirmed)
10/04/2023
Fiscal Year End
5/31/2024

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:ANGO
CUSIP
03475V10
Employees
815
Year Founded
1988

Price Target and Rating

Average Stock Price Forecast
$17.33
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$13.00
Forecasted Upside/Downside
+135.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-52,440,000.00
Pretax Margin
-16.07%

Debt

Sales & Book Value

Annual Sales
$338.75 million
Cash Flow
$1.11 per share
Book Value
$9.64 per share

Miscellaneous

Free Float
37,727,000
Market Cap
$291.97 million
Optionable
Optionable
Beta
0.61

Social Links

Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. James C. ClemmerMr. James C. Clemmer (Age 59)
    CEO, Pres & Director
    Comp: $1.51M
  • Mr. Stephen A. TrowbridgeMr. Stephen A. Trowbridge (Age 49)
    Exec. VP & CFO
    Comp: $709.57k
  • Mr. David D. Helsel (Age 59)
    Sr. VP of Global Operations and R&D
    Comp: $573.85k
  • Mr. Chad T. CampbellMr. Chad T. Campbell (Age 52)
    Sr. VP and GM of Vascular Access & Oncology Global Bus. Unit
    Comp: $544.19k
  • Ms. Laura Piccinini (Age 54)
    Sr. VP & GM of International
    Comp: $634.52k
  • Mr. Benjamin H. Davis (Age 59)
    Sr. VP of Bus. Devel.
  • Ms. Marna I. Bronfen-Moore (Age 56)
    Sr. VP of HR
  • Mr. Warren G. Nighan (Age 54)
    Sr. VP of Quality & Regulatory Affairs
  • Ms. Kim L. Seabury (Age 56)
    Sr. VP of Information Technology
  • Mr. Scott CenteaMr. Scott Centea (Age 44)
    Sr. VP & GM of Endovascular Therapies













ANGO Stock - Frequently Asked Questions

Should I buy or sell AngioDynamics stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AngioDynamics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ANGO shares.
View ANGO analyst ratings
or view top-rated stocks.

What is AngioDynamics' stock price forecast for 2023?

3 analysts have issued 1 year price targets for AngioDynamics' shares. Their ANGO share price forecasts range from $13.00 to $20.00. On average, they expect the company's stock price to reach $17.33 in the next twelve months. This suggests a possible upside of 135.5% from the stock's current price.
View analysts price targets for ANGO
or view top-rated stocks among Wall Street analysts.

How have ANGO shares performed in 2023?

AngioDynamics' stock was trading at $13.77 on January 1st, 2023. Since then, ANGO stock has decreased by 46.6% and is now trading at $7.36.
View the best growth stocks for 2023 here
.

Are investors shorting AngioDynamics?

AngioDynamics saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 1,850,000 shares, an increase of 51.6% from the August 31st total of 1,220,000 shares. Based on an average daily trading volume, of 650,100 shares, the short-interest ratio is currently 2.8 days. Approximately 4.9% of the shares of the stock are short sold.
View AngioDynamics' Short Interest
.

When is AngioDynamics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, October 4th 2023.
View our ANGO earnings forecast
.

How can I listen to AngioDynamics' earnings call?

AngioDynamics will be holding an earnings conference call on Wednesday, October 4th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 412-317-6671 with passcode "13741149".

How were AngioDynamics' earnings last quarter?

AngioDynamics, Inc. (NASDAQ:ANGO) posted its quarterly earnings results on Wednesday, July, 12th. The medical instruments supplier reported $0.02 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.02. The medical instruments supplier earned $91.10 million during the quarter, compared to analysts' expectations of $90.73 million. AngioDynamics had a negative net margin of 15.48% and a negative trailing twelve-month return on equity of 0.61%. The business's quarterly revenue was up 4.7% on a year-over-year basis. During the same period in the prior year, the company earned $0.01 EPS.

What guidance has AngioDynamics issued on next quarter's earnings?

AngioDynamics issued an update on its FY 2024 earnings guidance on Thursday, July, 13th. The company provided EPS guidance of -$0.34--$0.28 for the period, compared to the consensus EPS estimate of -$0.02. The company issued revenue guidance of $328.00 million-$333.00 million, compared to the consensus revenue estimate of $353.62 million.

What is James C. Clemmer's approval rating as AngioDynamics' CEO?

34 employees have rated AngioDynamics Chief Executive Officer James C. Clemmer on Glassdoor.com. James C. Clemmer has an approval rating of 50% among the company's employees. This puts James C. Clemmer in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 47.0% of employees surveyed would recommend working at AngioDynamics to a friend.

What other stocks do shareholders of AngioDynamics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AngioDynamics investors own include General Electric (GE), Intel (INTC), Oasis Petroleum (OAS), Advanced Micro Devices (AMD), Freeport-McMoRan (FCX), Amicus Therapeutics (FOLD), Rigel Pharmaceuticals (RIGL), Accuray (ARAY), Celldex Therapeutics (CLDX) and Chimerix (CMRX).

What is AngioDynamics' stock symbol?

AngioDynamics trades on the NASDAQ under the ticker symbol "ANGO."

Who are AngioDynamics' major shareholders?

AngioDynamics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (18.62%), Dimensional Fund Advisors LP (5.35%), State Street Corp (4.51%), Victory Capital Management Inc. (3.67%), The Manufacturers Life Insurance Company (2.29%) and Paradigm Capital Management Inc. NY (2.05%). Insiders that own company stock include Chad Thomas Campbell, Dave Helsel, James C Clemmer, James C Clemmer, Scott Centea, Stephen A Trowbridge and Wesley Johnson.
View institutional ownership trends
.

How do I buy shares of AngioDynamics?

Shares of ANGO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AngioDynamics' stock price today?

One share of ANGO stock can currently be purchased for approximately $7.36.

How much money does AngioDynamics make?

AngioDynamics (NASDAQ:ANGO) has a market capitalization of $291.97 million and generates $338.75 million in revenue each year. The medical instruments supplier earns $-52,440,000.00 in net income (profit) each year or ($1.32) on an earnings per share basis.

How many employees does AngioDynamics have?

The company employs 815 workers across the globe.

Does AngioDynamics have any subsidiaries?
The following companies are subsidiares of AngioDynamics: AngioDynamics Canada Inc., AngioDynamics France SARL, AngioDynamics Medical Brasil Participacoes Ltda., AngioDynamics Netherlands B. V., AngioDynamics UK Limited, AngioDynamics VA LLC, Clinical Devices, Eximo Medical Ltd., FlowMedica, NM Holding Company Inc., Navilyst Medical Holdings Inc., Navilyst Medical Inc., Oncovionic, RITA Medical Systems, RITA Medical Systems LLC, RadiaDyne LLC, and Vortex Medical.
Read More
How can I contact AngioDynamics?

AngioDynamics' mailing address is 14 PLAZA DRIVE, LATHAM NY, 12110. The official website for the company is www.angiodynamics.com. The medical instruments supplier can be reached via phone at (518) 795-1400, via email at mpolyviou@evcgroup.com, or via fax at 518-795-1401.

This page (NASDAQ:ANGO) was last updated on 9/28/2023 by MarketBeat.com Staff

My Account -